Advertisement

Agents and Actions

, Volume 13, Issue 1, pp 88–90 | Cite as

Clinical pharmacology of platinum complexes and their possible usefulness outside oncology

  • P. N. Plowman
Bioinorganic Interactions Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    B. Rosenberg, L. Van Camp andL. Krigas,Inhibition cell division in E. Coli by electrolysis products from a platinum electrode, Nature250, 698–699 (1965).Google Scholar
  2. [2]
    F. Basolo andR.G. Pearson, InMechanisms of Inorganic Reactions, 2nd ed., pp. 23, 355. Wiley, New York 1967,Google Scholar
  3. [3]
    R.W. Talley, R.M. O'Bryan, J.U. Gutterman et al.,Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875) — phase I clinical study, Cancer Chemother. Rep.57, 465–471 (1973).PubMedGoogle Scholar
  4. [4]
    M. J. Cleare andJ.D. Hoeschek,Antitumour activity of group IX transition metal complexes. I Platinum (on II) complexes. Bio-inorg. Chem.2, 187–210 (1973).Google Scholar
  5. [5]
    J.A. Howle andG.R. Gale,Cis-dichlorodiamineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo, Biochem. Pharmac.19, 2757–2762 (1970).CrossRefGoogle Scholar
  6. [6]
    A.T. Lippman, C. Helson, L. Helson et al.,Clinical trials of cis-diaminedichloroplatinum (NSC 119875), Cancer Chemother. Rep.57, 191–195 (1973).PubMedGoogle Scholar
  7. [7]
    F.K.V. Leh andW. Wolf,Platinum complexes: A new class of anti-neoplastic agents, J. Pharma. Sci.65, 315–328 (1976).Google Scholar
  8. [8]
    H.D. Kelman, H.J. Peresie andP.J. Stone,An analysis of the modes of binding of anti-tumour platinum complexes to D.N.A., Wadley Med. Bull.7, 440–448 (1977).Google Scholar
  9. [9]
    A. Khan, S. Hogan andJ.M. Hill,Immunosuppressive effects of sulfato-trans-(−)-1,2-diaminocyclohexane platinum(II). Cancer Res.39, 3476–3478 (1979).PubMedGoogle Scholar
  10. [10]
    A.W. Prestayko, J.C. D'Aoust, B.F. Issell et al,Cis-platin, Cancer Treatment Rev.6, 17–39 (1979).Google Scholar
  11. [11]
    C.L. Litterst, T.E. Gram, R.L. Dedrick et al.,Distribution and disposition of platinum following intravenous administration of cis-diaminedichloroplatinum(II) (NSC 119875) to dogs, Cancer Res.36, 2340–2344 (1976).PubMedGoogle Scholar
  12. [12]
    D.M. Hayes, E. Cvitkovic, R.B. Golbey et al., High dose cis-platinum diammine dichloride — Amelioration of renal toxicity by mannitol diuressi, Cancer39, 1372–1381 (1977).PubMedGoogle Scholar
  13. [13]
    M. Rozencweig,Cis-diammine dichloroplatimum(II): a new anti-cancer drug. Ann. intern. Med.86, 803–809 (1977).PubMedGoogle Scholar
  14. [14]
    A. Khan, K. Wakasugi, B. Hill et al,Platinum complexes: immunology and allergy, J. Clin. Haematol. Oncol.7(2), 797–813 (1977).Google Scholar
  15. [15]
    E.P. Getaz, S. Beckley, J. Fitzpatrick et al.,Cis-platin induced haemolysis, New Engl. J. Med.302, 334–335 (1979).Google Scholar
  16. [16]
    H.S. Thompson andG.R. Gale,Cis-dichlorodiamine platinum(II): haematopoietic toxicity in rats, The Pharmacologist12, 281–289 (1970).Google Scholar
  17. [17]
    H.S. Thompson andG.R. Gale,Cis-dichlorodiammineplatinum(II): haematopoietic toxicity in rats. Toxic. appl. Pharmac.19, 602–609 (1971).CrossRefGoogle Scholar
  18. [18]
    J.R. Bowen, G.R. Gale, W.A. Gardner et al.,Cis-diaminedichloroplatinum(II): suppression of adjuvant induced arthritis in rats, Agents and Actions4(2), 108–112 (1974).CrossRefPubMedGoogle Scholar
  19. [19]
    J.A. Howle, H.S. Thompson, A.E. Stone et al.,Cis-dichlorodiammine platinum(II): inhibitions of nucleic acid synthesis in lymphocytes stimulated with phytohaemagglutinin, Proc. Soc. exp. Biol. Med.137, 820–825 (1971).PubMedGoogle Scholar
  20. [20]
    A. Khan andJ.M. Hill,Inhibition of lymphocytes blastogenesis by platinum compounds, J. Surg. On col.3, 565–568 (1971).Google Scholar
  21. [21]
    A. Khan andJ.M. Hill,Suppression of lymphocyte blastogenesis in man following cis platinous diammine dichloride administration, Proc. Soc. exp. Biol. Med.142, 324–330 (1973).PubMedGoogle Scholar
  22. [22]
    A. Khan andJ.M. Hill,Immunosuppression with cis-platinum(II) diammino-dichloride: effect on anitbody plaque forming spleen cells, Infect. Immun.4, 320–321 (1971).PubMedGoogle Scholar
  23. [23]
    A. Khan, A. Albayrak andJ.M. Hill,Effects of cis-platinous diamminodichloride on graft rejection: prolonged survival of skin grafts against the histocompatibility. Proc. Soc. exp. Biol. Med.14, 7–14 (1971).Google Scholar
  24. [24]
    A. Khan andJ.M. Hill,Suppression of graft versus host reaction by cis-platinum(II) diamminodichloride. Transplantation13, 55–62 (1972).PubMedGoogle Scholar
  25. [25]
    R.J. Speer, H. Ridgway andL.M. Mall,Malonato-1,2 diam-inocyclohexane platinum(II): a potential antitumour agent, Wadley Med. Bull.5, 335–339 (1975).Google Scholar

Copyright information

© Birkhäuser Verlag 1983

Authors and Affiliations

  • P. N. Plowman
    • 1
  1. 1.St Bartholomew's HospitalLondonUK

Personalised recommendations